The MVP Act is a top federal policy priority for AMCP. This important bipartisan bill will enhance Medicaid patient access to new, high-cost therapies by modernizing the framework for value-based purchasing arrangements.
On January 5, 2024, the Food and Drug Administration (FDA) issued a letter
authorizing the state of Florida’s Section 804 Importation Programs (SIP) proposal
(Authorization Letter).
